Related Experiment Videos

Palivizumab use in preterm neonates

S Kingston1, B P Murphy

  • 1Department of Neonatology, Cork University Maternity Hospital, Wilton, Cork.

Irish Medical Journal
|July 30, 2010
PubMed

Insights

Palivizumab use for preventing respiratory syncytial virus (RSV) in infants shows significant variation in Irish neonatal units. A national protocol is needed to standardize RSV immunoprophylaxis and manage costs effectively.

Area of Science:

  • Neonatal Medicine
  • Pediatric Infectious Diseases
  • Public Health Policy

Background:

  • Respiratory syncytial virus (RSV) is a primary cause of infant bronchiolitis.
  • Palivizumab is an immunoprophylactic agent recommended for high-risk infants.
  • Current practices for Palivizumab administration in Ireland lack uniformity.

Purpose of the Study:

  • To assess the current guidelines and practices for Palivizumab administration in Irish neonatal units.
  • To identify variations in protocols regarding infant eligibility criteria.
  • To evaluate the perceived impact and cost-effectiveness of Palivizumab.

Main Methods:

  • A national survey was conducted among Consultant Neonatologists/Paediatricians in 20 Irish maternity centers.
  • Questionnaires focused on existing Palivizumab administration guidelines and protocols.
  • Data on protocol variations, perceived impact, and cost-effectiveness were collected.

Main Results:

  • Significant variability exists in Palivizumab administration protocols across Irish neonatal units.
  • Inconsistent criteria were reported regarding infant age and chronic lung disease status.
  • While some centers reported reduced hospital admissions, a national protocol is deemed necessary due to cost implications.

Conclusions:

  • There is a critical need for a unified national protocol for RSV immunoprophylaxis in Ireland.
  • Standardizing Palivizumab use can optimize resource allocation and ensure consistent patient care.
  • Addressing pharmacoeconomic constraints requires a national approach to RSV prevention strategies.

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Acute Respiratory Failure-IV01:23

Acute Respiratory Failure-IV

Respiratory failure can manifest suddenly or gradually, characterized by a rapid decline in PaO2 and a rapid rise in PaCO2. This situation indicates a severe respiratory problem that may quickly become a life-threatening emergency. One of the early signs of hypoxemic Acute Respiratory Failure (ARF) is a change in mental status due to the brain's sensitivity to oxygen levels and changes in acid-base balance. Symptoms such as restlessness, confusion, and agitation suggest inadequate oxygen...
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include: